Roles
- Director, Donald Soffer Endowed Program in Regenerative Medicine
- Senior Associate Dean for Experimental & Cellular Therapeutics
- Louis Lemberg Professor of Medicine (Cardiology)
- Professor of Molecular and Cellular Pharmacology
- Professor of Biomedical Engineering
- Director, Interdisciplinary Stem Cell Institute (ISCI)
- Secondary Appointment of Biochemistry and Molecular Biology
- Professor
-
Biography
Dr. Hare graduated from the University of Pennsylvania and has a medical degree from Johns Hopkins University. He did his residency at Hopkins and fellowships at Hopkins, Harvard University and The Brigham and Women’s Hospital in Boston. Dr. Hare was Professor of Medicine and Biomedical Engineering and director of cardiac transplantation at Johns Hopkins, leading their heart failure program, before he joined the faculty at University of Miami.
Dr. Hare is one of the world’s leading pioneers in the use of stem cell therapy to repair damaged hearts. He recently released findings on the first human clinical trial testing a stem-cell based treatment for heart attack patients, which showed the stem cell treated patients had lower rates of cardiac arrhythmias, and had significant improvements in heart, lung and symptom status. His work is widely published and has included recent articles in The New England Journal of Medicine, Nature, Proceedings of the National Academy of Sciences, Circulation, and Circulation Research”.
Dr. Hare is the principal investigator on a National Institutes of Health Specialized Center for Cell-Therapy (SCCT) funded stem cell study for patients with congestive heart failure. -
Education & Training
Education
Post Graduate Training
-
Research Interests
Stem cells, cardiology regenerative medicine -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Miller School of Medicine Stem Cell Research Advances to XPRIZE Healthspan Final
Miami Valves 2026 Showcases Latest in Valvular and Structural Heart Disease
Exosomes: The Insulin of Our Era?
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 6 clinical trials.
-
The purpose of this study is to measure safety and any benefits to the heart with AFTX-201, a gene therapy that is infused through an IV in participants with heart disease from mutations in a gene called BAG3.Participants will be followed for a total of 60 months post-treatment, with primary safety and efficacy assessments through Month 12, followed by long-term follow-up through Month 60.Study details include:• The study duration will be up to 5 years.• The treatment is a one-time treatment through an IV.• The visit frequency will be every day for the first week, then at Day 9 and 11, and then at week 2, 3, 4, and 6, month 2, 3, 6, 9 and 12 and then yearly from year 2 to 5.• Unscheduled visits are allowed.Number of Participants:• A maximum of 22 participants will be treated with the gene therapy AFTX-201
- Principal Investigator: Joshua Hare
- Study Phase: TBD
- Enrollment Status: Open
-
CATO is designed to answer two major questions: i) does IV cell therapy work in patients with ischemic HF? and ii) are multiple doses superior to a single dose? The ability to simultaneously address two major questions in one study underscores the cost-effectiveness of CATO. If the answer to either (or both) of these questions is affirmative, CATO would be the first trial to demonstrate the efficacy of two novel strategies (IV cell therapy; repeated cell therapy), each of which could revolutionize the field, not only in cardiovascular medicine, but in other disciplines as well. Either of these two new strategies would constitute a paradigm shift. Thus, the potential impact of this trial is very high.
- Principal Investigator: Joshua Hare
- Study Phase: Phase II
- Enrollment Status: Open
-
AB-1002 is a gene therapy product being developed as a one-time intracoronary infusion for the treatment of subjects with Congestive Heart Failure (CHF)
- Principal Investigator: Joshua Hare
- Study Phase: TBD
- Enrollment Status: Not Accepting
-
Mesenchymal Stem Cells transplantation for Patients with Heart Failure:Stem cell therapy for repair of damaged cardiac tissue is an attractive option to improve the health of the growing number of heart failure patients. Mesenchymal stem cells (MSCs) possess unique properties that may make them a better option for cardiac repair than other cell types. Unlike other adult stem cells, they appear to escape allorecognition by the immune system and they have immunemodulating properties, thus making it possible to consider them for use as an allogeneic cell therapy product. There is a large and growing body of preclinical and early clinical experience with MSC therapy that shows great promise in realizing the potential of stem cell therapy to effect repair of damaged cardiac tissue. Still, the underlying mechanisms of improved left ventricular function due to mesenchymal stem cells administration is not clear enough. It has been shown that mesenchymal stem cell transplantation postmyocardial infarction caused myocardial regeneration and neovascularization, probably through increased tissue perfusion. Interestingly, mesenchyaml stem cellstreated animals showed larger, more mature vessels and less apoptosis in the infarct zones and improved regional and global LV function at week 8 post transplantation. These findings suggest that an early increase in tissue perfusion precedes improvements in LV function and a reduction in apoptosis in mesenchymal stem cellstreated hearts. We believe that part of the beneficial effects demonstrated in mesenchymal stem cell transplantation for heart failure could be attributed to neovascularization and cytokine relased from the transplanted heart muscle or from the mesenchymal stem cells that were injected to the myocardium. In order to study those pleotrophic effects of mesenchymal stem cell transplantation we will conduct a prospective trial where we will measure in vivo endothelial function (the brachial artery method flow mediated dilatation percent change) and the ankle brachial index (ABI) as markers of vascular responsiveness of patients with heart failure, before and after the transplantation, and in control heart failure patients not undergoing transplantation, and in vitro we will study the ability of patients to produce endothelial progenitor stem cells colonies (Colony Forming Unit Hill Colony Assay). Primary Objective: In order to study those pleotrophic effects of mesenchymal stem cell transplantation we will conduct a prospective trial where we will measure in vivo endothelial function (the brachial artery method flow mediated dilatation percent change) before and after the cell injection. Secondary Objectives:1. To study the effects of mesenchymal stem cell transplantation on the endothelial progenitor stem cells function by measuring the ability of patients to produce endothelial progenitor stem cells colonies (the Colony Forming UnitHill Colony Assay). This assay has been demonstrated as a marker of cardiovascular risk, but was not studied in patients with heart failure.2. To measure the proinflammatory cytokine profile before and after cell therapy.3. To correlate our findings with clinical parameters of heart failure.Risks:There are mild risks and discomforts involved in the ultra sound imaging of the brachial artery including the following: feeling of tightness in the arm below the transducer for a few minutes.There could be mild risk from blood withdrawal: mild bleeding, small hematoma, pain and discomfort.
- Principal Investigator: Joshua Hare
- Study Phase: N/A
- Enrollment Status: Closed
-
A Phase IIB Randomized, Placebo-Controlled, Multicenter Study of the Comparative Efficacy and Safety of Transendocardial Injection of Allogeneic-MSC Versus Placebo in Patients With Non- Ischemic Dilated Cardiomyopathy
- Principal Investigator: Joshua Hare
- Study Phase: Phase 2
- Enrollment Status: Open
-
To be able to better understand how endothelial function and immune biomarker testing can help to learn about inflammatory conditions.
- Principal Investigator: Joshua Hare
- Study Phase: N/A
- Enrollment Status: Closed